MET receptor tyrosine kinase as a therapeutic anticancer target |
| |
Authors: | Christine M. Stellrecht Varsha Gandhi |
| |
Affiliation: | 1. Department of Experimental Therapeutics, Unit 71, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA;2. Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA |
| |
Abstract: | Tyrosine kinases are frequently deregulated in cancer either by constitutive activation, mutation, or over-expression. Though they are often associated with an aggressive phenotype they are also proving to be a druggable target. Activation of the MET receptor tyrosine kinase promotes cell proliferation, scattering, invasion, survival, and angiogenesis. Deregulation of MET promotes tumor formation, growth, progression, metastasis, and therapeutic resistance. Because MET is a player in so many aspects of cancer development and progression, it is a strong candidate for targeted therapy. Numerous agents have been developed that are able to target MET expression and/or function and are the focus of this review. |
| |
Keywords: | Met Receptor tyrosine kinase Targeted therapy Hepatocyte growth factor |
本文献已被 ScienceDirect 等数据库收录! |
|